Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.

Abstract

INTRODUCTION:

Somatostatin (SST) receptor ligands (SRL), in particular those of first generation (Octreotide and Lanreotide), are widely used in medical treatment of acromegaly, but they assure biochemical control of disease (and the possibility of an improvement of clinical symptoms and tumor shrinkage), only in a subset of patients.

DISCUSSION:

The mechanisms underlying the so called "SRL resistance" are various and involve in particular SST receptor expression and molecular pathways of signal transduction. Different predictors of SRL response have been reported, including clinical and biochemical features (gender, age, growth hormone and insulin-like growth factor-I levels at diagnosis), and tumor characteristic (both at preoperative magnetic resonance imaging study and histopathology) as well as expression of SST receptors. In some cases, only a "partial resistance" to SST can be detected, probably due to the presence of other impaired molecular mechanisms involved in signal transduction, which compromise specific pathways and not others. This may explain some cases of dissociated response between biochemical control and tumor shrinkage.

• Authors: Rosa Maria Paragliola, Salvatore Maria Corsello, Roberto Salvatori
• Journal: Pituitary (Pituitary) Vol. 20 Issue 1 Pg. 109-115 (Feb 2017) ISSN: 1573-7403 [Electronic] United States
• PMID: 27778296 (Publication Type: Journal Article, Review)

Chemical References

• Peptides, Cyclic
• Receptors, Somatostatin
• lanreotide
• Somatostatin
• pasireotide
• Octreotide

Topics

• Acromegaly (drug therapy, metabolism)
• Female
• Humans
• Male
• Octreotide (therapeutic use)
• Peptides, Cyclic (therapeutic use)
• Receptors, Somatostatin (agonists, metabolism)
• Somatostatin (analogs & derivatives, therapeutic use)